Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.50 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 7/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | CNR1 | P21554 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL27712981 | 0.97 | MRGPRX4 (0.48) | MRGPRX4CXCR2SLC6A5DRD4CNR2 | |
| SCHEMBL486088 | 0.89 | MRGPRX4 (0.56) | MRGPRX4CXCR2SLC6A5DRD4CNR2 | |
| SCHEMBL485710 | 0.87 | MRGPRX4 (0.56) | MRGPRX4CXCR2SLC6A5DRD4CNR2 | |
| SCHEMBL485784 | 0.87 | CXCR2 (0.44) | MRGPRX4CXCR2CNR2CNR1MEN1 | |
| SCHEMBL485799 | 0.87 | MRGPRX4 (0.45) | MRGPRX4 | |
| Formic Acid SCHEMBL27693269 | 0.87 | MRGPRX4 (0.54) | MRGPRX4CXCR2SLC6A5DRD4CNR2 | |
| SCHEMBL485699 | 0.86 | CXCR2 (0.62) | MRGPRX4CXCR2SLC6A5DRD4CNR2 | |
| SCHEMBL485687 | 0.85 | MRGPRX4 (0.45) | MRGPRX4CNR2CNR1 | |
| Formic Acid SCHEMBL27713047 | 0.85 | CXCR2 (0.58) | MRGPRX4CXCR2SLC6A5DRD4CNR2 | |
| Formic Acid SCHEMBL27693250 | 0.85 | MRGPRX4 (0.43) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836158-B1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-02-01 | — | — | EP | claimed |